

Elena Zerkalenkova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219488/publications.pdf>

Version: 2024-02-01

35
papers

886
citations

932766

10
h-index

500791

28
g-index

36
all docs

36
docs citations

36
times ranked

1812
citing authors

#	ARTICLE	IF	CITATIONS
1	The MLL recombinome of acute leukemias in 2017. <i>Leukemia</i> , 2018, 32, 273-284.	3.3	527
2	Mitochondrial membrane potential is regulated by vimentin intermediate filaments. <i>FASEB Journal</i> , 2015, 29, 820-827.	0.2	73
3	Vimentin is involved in regulation of mitochondrial motility and membrane potential by Rac1. <i>Biology Open</i> , 2015, 4, 1290-1297.	0.6	50
4	± ² T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation without Antithymocyte Globulin in Children with Chemorefractory Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e179-e182.	2.0	31
5	Relative expansion of CD19 ⁺ early normal B ⁺ cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR ⁺ cell therapy: implications for flow cytometric detection of minimal residual disease. <i>British Journal of Haematology</i> , 2021, 193, 602-612.	1.2	30
6	Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. <i>Blood</i> , 2022, 140, 1875-1890.	0.6	26
7	Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab. <i>Haematologica</i> , 2021, 106, 2009-2012.	1.7	18
8	Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4019.	1.8	18
9	Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. <i>Annals of Hematology</i> , 2018, 97, 977-988.	0.8	15
10	B ⁺ lineage antigens that are useful to substitute <sc>CD19</sc> for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after <sc>CD19</sc> targeting. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 353-359.	0.7	11
11	A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23). <i>Cancer Genetics</i> , 2015, 208, 148-151.	0.2	9
12	Quantification of NG2 ⁺ positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 88-99.	1.5	8
13	Blinatumomab following haematopoietic stem cell transplantation – a novel approach for the treatment of acute lymphoblastic leukaemia in infants. <i>British Journal of Haematology</i> , 2021, 194, 174-178.	1.2	8
14	A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A ⁺ USP10 fusion gene. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 522-524.	1.5	7
15	Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2803-2811.	1.2	7
16	Acute myeloid leukemia with t(10;11)(p11 ⁺ q23.3): Results of Russian Pediatric AML registration study. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 287-292.	0.7	6
17	Strong expansion of normal CD19 ⁺ B ⁺ cell precursors after the use of blinatumomab in the first ⁺ line therapy of acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	6
18	Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells. <i>Haematologica</i> , 2022, 107, 970-974.	1.7	6

#	ARTICLE	IF	CITATIONS
19	BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia. <i>Biomedicines</i> , 2021, 9, 924.	1.4	5
20	Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow–Berlin (MB). <i>Leukemia and Lymphoma</i> , 2019, 60, 426-432.	0.6	4
21	Cytogenetic and molecular genetic methods for chromosomal translocations detection with reference to the <i>KMT2A/MLL</i> gene. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 180-206.	2.7	3
22	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2021, 100, 106491.	0.4	3
23	Lineage switch in relapse of acute leukemia with rearrangement of MLL gene (KMT2A). literature review and case reports. <i>Oncogematologiya</i> , 2016, 11, 21-29.	0.1	2
24	Molecular characterization of pediatric acute myeloid leukemia with t(8;21). <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2018, 17, 9-15.	0.1	2
25	HETEROGENEITY OF CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EGIL SUBTYPE BIV). <i>Oncogematologiya</i> , 2018, 12, 34-40.	0.1	2
26	Immunophenotypic characterization of acute megakaryoblastic leukaemia in children. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019, 18, 35-40.	0.1	2
27	The Absence of Retroelement Activity Is Characteristic for Childhood Acute Leukemias and Adult Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1756.	1.8	2
28	Vimentin Protects Cells Against Doxorubicin and Vincristine. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2018, 12, 255-260.	0.3	1
29	The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report. <i>Leukemia Research</i> , 2021, 110, 106662.	0.4	1
30	T-cell-depleted haploidentical hematopoietic stem cell transplantation in children with chemorefractory acute myeloid leukemia. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019, 18, 11-21.	0.1	1
31	Novel KMT2A Partner Gene NUTM2A Revealed By Anchored Multiplex PCR in ALL. <i>Blood</i> , 2019, 134, 5203-5203.	0.6	1
32	Infant Acute Myeloid Leukemia with t(X;6)(p11;q23)/MYB-GATA1 - a First Female Case in the Entity. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
33	Rare cases of laboratory tests discrepancies in diagnostics of pediatric Burkitt lymphoma/leukemia. <i>Oncogematologiya</i> , 2018, 13, 76-82.	0.1	0
34	The effectiveness of the information system for managing data from a registration study of acute myeloid leukemia in children. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019, 18, 144-151.	0.1	0
35	Bruton's Tyrosine Kinase (BTK) Is a Novel KMT2A Partner Gene. <i>Blood</i> , 2019, 134, 5192-5192.	0.6	0